Creative Medical Technology Announced That The FDA Has Cleared The Company To Proceed With A Phase 1/2 Trial Of Stemspine Using Allostem; The Study Will Enroll 30 Individuals Suffering From Chronic Lower Back Pain
Portfolio Pulse from Benzinga Newsdesk
Creative Medical Technology has received FDA clearance to proceed with a Phase 1/2 trial of StemSpine using AlloStem. The study will enroll 30 individuals suffering from chronic lower back pain.
September 19, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Creative Medical Technology, listed as CELZ, has received FDA clearance for a Phase 1/2 trial, which could potentially lead to positive outcomes for the company.
FDA clearance for a Phase 1/2 trial is a significant milestone for any biotech company. This clearance allows Creative Medical Technology to proceed with their trial, which if successful, could lead to a new product offering and potential revenue growth. This is directly relevant to CELZ and could have a positive impact on their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100